H. Lundbeck A/S- (NASDAQ:HLUYY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Monday.

According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “

Separately, Jefferies Group LLC lowered shares of H. Lundbeck A/S- from a “buy” rating to a “hold” rating in a research note on Tuesday, April 11th.

Shares of H. Lundbeck A/S- (HLUYY) traded up 0.96% during mid-day trading on Monday, hitting $57.93. 2,053 shares of the company traded hands. The firm has a market cap of $11.43 billion and a price-to-earnings ratio of 46.09. The firm has a 50-day moving average price of $53.03 and a 200 day moving average price of $46.19. H. Lundbeck A/S- has a 52-week low of $31.00 and a 52-week high of $60.78.

TRADEMARK VIOLATION WARNING: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/07/17/h-lundbeck-as-hluyy-lowered-to-hold-at-zacks-investment-research.html.

H. Lundbeck A/S- Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Get a free copy of the Zacks research report on H. Lundbeck A/S- (HLUYY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.